Healthcare Industry News: Collagenase
News Release - February 2, 2007
AGI Dermatics Data Shows Efficacy of Bicyclic Monoterpene Diols in Treatment of Molecular Markers of PhotoAged Skin
Positive Data Presented at Annual Meeting of the American Academy of DermatologyFREEPORT, N.Y., Feb. 2 (HSMN NewsFeed) -- AGI Dermatics today announced new clinical research that indicates bicyclic monoterpene diols (BMTd) are effective agents in treating photodamaged skin by significantly increasing collagen production and decreasing production of Collagenases. The clinical study was presented in the Poster Session at the 65th Annual Meeting of the American Academy of Dermatology in Washington, DC.
"Our clinical study suggests BMTd compounds are useful in maintaining high collagen levels within the layers of sun-exposed skin," said Dan Yarosh, PhD, President, AGI Dermatics. "This is extremely valuable when we consider the existing data that shows BMTds increase nitric oxide levels and play a major role in collagen synthesis."
The study examined the effects of BMTds on both collagen production and expression of Collagenase, specifically metalloproteinase-1 (MMP-1). Collagenases, such as metalloproteinase-1 (MMP-1), degrade collagen resulting in the damage of the dermal matrix as expressed as wrinkles, a molecular marker for aging.
Normal human dermal fibroblasts (NHDF) were treated with the equimolar mixture of a BMTd compound (2,3 cis.exo-pinandediol and 2,3-cis/exo- camphanediol) for 48 hours or 7 days. The treatment of NHDF with BMTd showed a promotion of collagen expression and a significant 91 percent increase in collagen production when compared to untreated samples. Results were measured by RT-PCR, ELISA and immunohistochemistry. At the same time, ELISA measurements indicated a significant 30 percent decrease in MMP-1 production compared to untreated samples.
The study also examined MMP-1 expression production controlled indirectly through a paracine mechanism: conditioned media from normal human epidermal keratinocytes (NHEK) that were irradiated with UVB, incubated for 24 hours and transferred to NHDF for 48 hours. A significant decrease of 31 percent was seen in MMP-1 production with treatment of the UVB stimulated NHEK with BMTds.
"We know photodamage accounts for nearly all of the symptoms of premature skin aging, and wrinkles associated with aging result in a decrease in collagen," said Dr. Yarosh. "The data suggest that BMTd compounds can play a promising role in treating the underlying causes of wrinkles in addition to known benefits in promoting increased circulation by boosting nitric acid levels."
AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent Microcirculation Therapy features Pinoxide(TM), an exclusive and patented blend of BMTds. Clinical studies prove Pinoxide(TM) speeds blood flow, warms the skin, increases resistance to cold, and reduces dark under-eye symptoms. The new research presented in today's poster suggests Pinoxide(TM) may also contribute to promoting firmness and resiliency in the skin.
About AGI Dermatics
AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com
Source: AGI Dermatics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
